ZNTL — Zentalis Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Zentalis Pharmaceuticals Q3 net loss narrows
Brief: Zentalis Pharmaceuticals Q3 EPS USD -0.37
Brief: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zentalis Pharmaceuticals Appoints James B. Bucher, JD, As Chief Legal Officer And Corporate Secretary
Zentalis Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Zentalis Pharmaceuticals Q2 EPS USD -0.37
Zentalis Pharmaceuticals Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Zentalis Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Zentalis Pharmaceuticals Q1 Operating Expenses USD 45.623 Million
Zentalis Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Zentalis Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Zentalis Pharmaceuticals Inc Files For Mixed Shelf Of Up To $250 Million - SEC Filing
Zentalis Pharmaceuticals Inc expected to post a loss of 71 cents a share - Earnings Preview
Zentalis Pharmaceuticals Inc expected to post a loss of 71 cents a share - Earnings Preview
Zentalis Pharmaceuticals Inc expected to post a loss of 71 cents a share - Earnings Preview
Zentalis Pharmaceuticals Inc expected to post a loss of 71 cents a share - Earnings Preview
Brief: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)